ELI LILLY & Co — Form 8-K
Filed October 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 42/100
What the filing says
ELI LILLY reports Q3 2026 revenue of $24.4 billion (39% YoY growth), beating prior expectations, with Mounjaro revenues at $10.7 billion (+65%) and Zepbound at $5.4 billion (+49%). The company raised full-year 2026 revenue guidance by $5.5 billion to $91–$92 billion and increased non-GAAP EPS guidance midpoint by $4.07 (before offsetting $4.57 of IPR&D charges from business development), resulting in revised EPS range of $35.00–$36.00. Concurrently, Lilly completed the acquisition of AtaiBeckley (treatment-resistant depression) in Q3 and announced the acquisition of Merida Biosciences (autoimmune/allergic diseases) post-quarter end; specific acquisition prices were not disclosed.
Why this rating
Revenue and EPS guidance raises are meaningful but modest relative to $807.9B market cap (~0.7% revenue increase). GLP-1 dominance confirmed but pricing pressure evident (15–29% price declines); business development adds long-term potential but near-term IPR&D charges offset gains. Ordinary quarterly beat, not business trajectory shift.
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.